Education
About Us
Working with TipRanks
Follow Us
Moderna (IT:1MRNA)
:1MRNA
Earnings Data
Report Date
Jul 31, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-2.64Last Year’s EPS
-2.95Same Quarter Last Year
Based on 20 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:May 01, 2025
|% Change Since: -20.08%
|Next Earnings Date:Jul 31, 2025
Earnings Call Sentiment|Neutral
Moderna has made significant progress in cost reduction and market expansion, particularly in the oncology and international vaccine markets. However, the company still faces challenges with declining revenues, significant net losses, and extended regulatory review timelines for key products.Company Guidance
During the Moderna first quarter 2025 conference call, the company provided detailed guidance on various financial and operational metrics. For Q1 2025, Moderna reported revenues of $0.1 billion with a net loss of $1 billion, aligning with their expectations due to the seasonal nature of their respiratory vaccine business. They ended the quarter with $8.4 billion in cash and investments. Moderna achieved a 19% reduction in combined cost of sales, R&D, and SG&A expenses compared to Q1 2024. Net product sales were $86 million, mainly from COVID vaccine sales, with the U.S. contributing about one-third of these sales. The company expects total revenue for 2025 to range between $1.5 billion and $2.5 billion, with projected cost of sales at approximately $1.2 billion. R&D expenses are anticipated to be $4.1 billion for the year, while SG&A expenses are expected to be around $1.1 billion. Looking ahead, Moderna plans to drive $1.4 billion to $1.7 billion in cost reductions by 2027, aiming for a cash cost of $4.2 billion that year. The company continues to focus on expanding its product portfolio, with advancements in its oncology pipeline and ongoing late-stage trials for several vaccines.Cost Reduction Achievements
Moderna achieved a 19% reduction in combined R&D, SG&A, and cost of sales compared to Q1 2024. This marks the third consecutive quarter of double-digit year-over-year declines in these expenses.
Expansion of Commercial Markets
Moderna expanded its commercial reach by receiving approvals for its mRESVIA vaccine in Australia, Taiwan, the UK, and Switzerland, in addition to previous approvals in the US, EU, and Canada.
Oncology Portfolio Expansion
Moderna announced the expansion of its oncology portfolio with the addition of the Checkpoint medicine program, showing early but encouraging data.
Strong Cash Position
Moderna ended Q1 2025 with $8.4 billion in cash and investments, maintaining a strong financial position despite a net loss for the quarter.
---
IT:1MRNA Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
IT:1MRNA Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 14, 2025 | €29.53 | €31.70 | +7.37% |
| Nov 07, 2024 | €48.22 | €48.00 | -0.46% |
| Aug 01, 2024 | €112.26 | €89.67 | -20.12% |
| May 02, 2024 | €106.30 | €110.90 | +4.33% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Moderna (IT:1MRNA) report earnings?
Moderna (IT:1MRNA) is schdueled to report earning on Jul 31, 2025, TBA Not Confirmed.
What is Moderna (IT:1MRNA) earnings time?
Moderna (IT:1MRNA) earnings time is at Jul 31, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Moderna stock?
The P/E ratio of Moderna is N/A.
What is IT:1MRNA EPS forecast?
IT:1MRNA EPS forecast for the fiscal quarter 2025 (Q2) is -2.64.
---
